<DOC>
	<DOCNO>NCT01263015</DOCNO>
	<brief_summary>The purpose trial ass non-inferior antiviral activity GSK1349572 50 mg plus Abacavir/Lamivudine daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate ( ATRIPLA® trade mark Bristol-Myers Squibb Gilead Sciences LLC ) 48 week ; non-inferiority also test Week 96 . This study conduct HIV-1 infect ART-naïve adult subject . Long term antiviral activity , tolerability , safety , development viral resistance evaluate .</brief_summary>
	<brief_title>A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily Atripla ( Also Called The SINGLE Trial )</brief_title>
	<detailed_description>ING114467 Phase 3 randomize , double-blind , double dummy , active-controlled , multicenter , study conduct approximately 788 HIV-1 infect ART-naïve subject . Subjects randomize 1:1 one follow treatment arm : GSK1349572 50 mg plus abacavir/lamivudine fixed-dose combination daily ( approximately 394 subject ) OR Atripla daily ( approximately 394 subject ) Analyses conducted 48 week 96 week . Subjects randomize receive GSK1349572 successfully complete 96 week treatment continue access GSK1349572 plus abacavir/lamivudine fixed-dose combination study locally available-as long continue derive clinical benefit , meet protocol-defined reason discontinuation , development compound terminate . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Screening plasma HIV1 RNA ≥1000 c/mL Antiretroviralnaïve ( ≤ 10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection ) Ability understand sign write informed consent form Willingness use approve method contraception avoid pregnancy ( woman child bear potential ) Age equal great 18 year A negative HLAB*5701 allele assessment Women pregnant breastfeeding ; Active Center Disease Prevention Control ( CDC ) Category C disease Hepatic impairment HBV coinfection Anticipated need HCV therapy study Allergy intolerance study drug component drug class Malignancy within past 5 year Treatment HIV1 immunotherapeutic vaccine within 90 day Screening Treatment radiation therapy , cytotoxic chemotherapeutic agent immunomodulator within 28 day Screening Exposure agent document activity HIV1 vitro experimental vaccine drug within 28 day first dose study medication Primary viral resistance Screening result Verified Grade 4 laboratory abnormality ALT &gt; 5 xULN ALT ≥ 3xULN bilirubin ≥ 1.5xULN ( &gt; 35 % direct bilirubin ) ; Estimated creatinine clearance &lt; 50 mL/min Recent history ( ≤3 month ) upper low gastrointestinal bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>Abacavir/Lamivudine</keyword>
	<keyword>Treatment-naive</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>Atripla</keyword>
</DOC>